Cancer's genetic heterogeneity presents a significant challenge to treatment, but recent advances in genomics are revolutionizing personalized medicine.  The identification of specific driver mutations, through techniques like next-generation sequencing, is crucial.  This allows for the stratification of patients into distinct molecular subtypes, moving beyond traditional histological classifications.  

For example, identifying EGFR mutations in lung cancer enables targeted therapy with tyrosine kinase inhibitors, offering significantly improved outcomes compared to generic chemotherapy.  Similarly, advancements in understanding the tumor microenvironment and immune checkpoints have led to the development of immunotherapy, tailored to specific genetic profiles influencing immune response.  Liquid biopsies, analyzing circulating tumor DNA, offer minimally invasive approaches to monitor disease progression and tailor treatment dynamically.

Ongoing research focuses on improving the accuracy and affordability of genomic profiling, expanding our understanding of complex interactions between genetic alterations, and developing novel therapies targeting specific oncogenic pathways.  These developments pave the way for truly personalized cancer treatment, maximizing efficacy and minimizing toxicity.